New Ductopenia and Donor-Specific Antibodies Five Years After Living-Donor Transplant
A 12-year-old girl who received a living-donor left lateral segment graft for biliary atresia at age 3 presents with 4 weeks of fatigue and pruritus. She admits to missing tacrolimus doses a few times a month during a school sports season. Today's tacrolimus trough is 3.1 ng/mL, previously 6–7; troughs over the past year were 2.4, 8.9, and 4.0. ALT 240 U/L, AST 180 U/L, GGT 410 U/L, ALP 520 U/L, total bilirubin 2.6 mg/dL, direct 1.8 mg/dL, albumin 3.4 g/dL, INR 1.2, platelets 88,000/µL. EBV PCR is under 200 copies/mL, CMV PCR is negative, and hepatitis E PCR is negative. MRCP shows multifocal intrahepatic bile duct stricturing with a patent anastomosis and no vascular thrombosis on Doppler. Class II donor-specific antibodies are newly detected with MFI 6,200. She is afebrile and blood cultures are negative.
1. What is your differential, and what is the immediate diagnostic step?
Read the worked answer
Differential:
- Chronic ductopenic rejection, with or without antibody-mediated rejection.
- Ischemic cholangiopathy from hepatic artery stenosis, thrombosis, or microvascular injury; MRCP shows the ducts, not the arterial supply, and Doppler can miss segmental stenosis.
- Biliary anastomotic or nonanastomotic strictures with ascending cholangitis; blood cultures negative does not exclude it.
- Recurrent or de novo autoimmune liver disease.
- Infection (CMV, EBV, hepatitis E, adenovirus), drug injury, and lymphoma/PTLD.
Immediate step: liver biopsy before any change in immunosuppression, with H&E, trichrome, cytokeratin-7 to count ducts per portal tract, C4d, and IgG4. Send tissue for EBV and CMV PCR. Add CT or MR angiography to assess the hepatic artery.
The class II DSA at MFI 6,200 is significant but not diagnostic - donor-specific antibodies can coexist with a normal graft. The combination of fluctuating tacrolimus troughs, rising GGT, and intrahepatic strictures makes rejection and ischemic injury the leading concerns.
2. The biopsy shows bile duct loss in 60% of portal tracts, arteriolar foam cells, and C4d positivity. What is your management, and what is the prognosis?
Read the worked answer
This is chronic rejection with features of chronic active antibody-mediated rejection. Ductopenia in more than 50% of portal tracts with arteriopathy is generally irreversible.
Management:
- Restore and intensify baseline immunosuppression: target tacrolimus trough 8–10 ng/mL, and add mycophenolate mofetil if she is not already on it. The first step is correcting the under-immunosuppression that likely precipitated this.
- For the antibody component, IVIG 1–2 g/kg, rituximab 375 mg/m², and plasma exchange are used in case series, but there is no strong pediatric evidence that they reverse established ductopenia. Offer them with explicit acknowledgment of limited evidence and with infectious and PTLD monitoring.
- A steroid bolus may treat coexisting acute cellular rejection but will not reverse duct loss. Do not reduce immunosuppression in response to the falling platelets and rising GGT.
- Treat biliary strictures on their own merits with ERCP dilation if accessible; this relieves pruritus and cholangitis even if rejection is also present.
Prognosis:
- Ductopenic rejection usually progresses to graft failure over months to years, though a minority stabilize. Repeat biopsy in 4–6 weeks and follow bilirubin, GGT, and synthetic function.
- Begin retransplant evaluation now rather than after decompensation, and screen for EBV reactivation while immunosuppression is intensified.
3. How do you address the adherence problem, and when should you list her for retransplant?
Read the worked answer
Adherence:
- Approach this as a systems problem, not a character flaw. Ask what changed during the sports season: dosing times, travel to games, forgetting supplies, or supervision at school.
- Convert to once-daily extended-release tacrolimus if available, set phone alarms, use a pillbox, involve the school nurse, and consider directly observed therapy or a family contract for a defined period.
- Quantify adherence with the coefficient of variation of trough levels and pharmacy refill data, not just the patient's report.
- Screen for depression, anxiety, and family stress; involve social work and psychology, and start transition planning since this is the age when adherence often collapses.
Listing for retransplant:
- Progressive graft dysfunction: rising bilirubin, falling albumin, rising INR, refractory pruritus, growth failure, or intractable portal hypertension such as recurrent variceal bleeding.
- Recurrent cholangitis that cannot be controlled endoscopically.
- In a child with established ductopenia and de novo donor-specific antibodies, start the evaluation early - before decompensation - because waiting for a high MELD/PELD score in a child with ductopenic rejection means waiting for a crisis.
Counsel the family that adherence problems are a risk factor, not a veto: retransplant outcomes are good, but the same behavior will threaten the second graft. Build the support plan before the operation, and document it.